STOCK TITAN

Ainos signs $9M AI Nose equipment sales agreement

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Ainos, Inc. (AIMD) reported revenue of $642,889 for the quarter ended September 30, 2026, compared with $2,167 a year earlier; nine-month revenue was $643,202 versus $113,037. Nine-month revenue included $600,000 from VELDONA intellectual-property licensing and $42,750 from AI Nose programs. The nine-month net loss was $8,940,605, compared with $10,302,714.

At September 30, cash and cash equivalents were $660,916, and operating activities used $3,429,677 in cash during the first nine months. Ainos later collected $950,000, comprising $600,000 of VELDONA licensing receivables and $350,000 from AI Nose semiconductor commercialization. The company said substantial doubt exists about its ability to continue as a going concern for at least one year from issuance, citing reliance on operating cash flows and future financing.

On November 12, 2026, Ainos entered a commercial sales agreement with ASE Technology Holding Co., Ltd. for 5,000 AI Nose units at a total purchase price of $9 million. The customer is to pay 50% within 60 days after signing and the balance upon completion and delivery of all equipment.

3 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointAinos entered a $9 million purchase agreement for 5,000 AI Nose units. 91% of market cap
  • Moderate pointNine-month revenue was $643,202, versus $113,037 in 2025.
  • Moderate pointNine-month net loss fell 13% to $8,940,605.

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.Substantial doubt about continuing as a going concern extends at least one year from issuance.

Filing Explained

At September 30, $11,000,000 in convertible notes and $2,812,940 in loans were current liabilities, with repayment dates in 2027.

By September 30, 2026, Ainos reported sales of $436,857 shares under its at-the-market program during the first nine months; its equity statement records 434,056 of those shares issued and 2,801 still to be issued. Outstanding common shares rose from 5,822,675 at year-end 2025 to 7,554,324 at quarter-end, increasing the share base and reducing existing holders’ percentage ownership, absent offsetting changes.

An at-the-market program permits gradual share sales at prevailing market prices, and the company says it is not obligated to sell. The July 24 supplement states an aggregate offering amount of up to $1,346,165; that is offering capacity, not evidence those additional shares were sold. The company reported $830,435 in net proceeds from ATM sales during the nine months and $2,839,156 in cumulative net proceeds through quarter-end.

At quarter-end, the balance sheet classified $11,000,000 in convertible notes and a $2,812,940 loan as current liabilities, against cash of $660,916. The notes are convertible; absent conversion, the $2,000,000 March note is due March 12, 2027 and the $9,000,000 note is due May 3, 2027; the loan’s NT$28 million portion is due March 27, 2027 and its NT$62 million portion July 31, 2027.

Quarterly revenue $642,889 Three months ended September 30, 2026; $2,167 in the same period of 2025
Nine-month revenue $643,202 Nine months ended September 30, 2026; $113,037 in the same period of 2025
Nine-month net loss $8,940,605 loss Nine months ended September 30, 2026; $10,302,714 loss in the same period of 2025
Cash and cash equivalents $660,916 As of September 30, 2026
Cash used in operating activities $3,429,677 Nine months ended September 30, 2026
Post-period collections $950,000 Collected after September 30, 2026; includes VELDONA licensing receivables and AI Nose commercialization activities
Agreement purchase price $9 million Commercial sales agreement for AI Nose equipment dated November 12, 2026
AI Nose units ordered 5,000 units Commercial sales agreement dated November 12, 2026
going concern financial
"substantial doubt exists about the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
Adjusted Net Loss financial
"we present Adjusted Net Loss, defined as net loss adjusted to exclude"
Adjusted net loss is the company’s reported net loss after removing one-time, non-cash, or unusual items that management says obscure underlying results, such as restructuring charges, asset write-downs, or stock-based pay. Investors use it to focus on the business’s core profitability — like smoothing out potholes to judge road quality — but should be cautious because choices about what to exclude can make performance look better than it really is.
at-the-market offering financial
"shares of its Common Stock, depending on market demand"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
Smell ID technical
"a machine-readable data format"
near-threshold detection technical
"develop AI Nose for near-threshold detection scenarios"
anti-dilutive financial
"excluded from the computations of diluted weighted average shares"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did AIMD report for the first nine months of 2026?

AIMD reported $643,202 in revenue for the nine months ended September 30, 2026, compared with $113,037 for the same period in 2025. The 2026 amount included $600,000 from VELDONA intellectual-property licensing and $42,750 from AI Nose programs.

What is the value and payment schedule of AIMD's AI Nose order?

Ainos entered an agreement with ASE Technology Holding Co., Ltd. for 5,000 AI Nose units at a total purchase price of $9 million. The customer is to pay 50% within 60 days after the November 12, 2026 agreement was signed, and the balance upon completion and delivery of all equipment.

Did AIMD report a going-concern warning?

Ainos said substantial doubt exists about its ability to continue as a going concern for at least one year from issuance of the financial statements. It also expects additional losses and negative operating cash flows for at least the next 12 months and depends on operating cash flows and future financing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false --12-31 Q3 0001014763 0001014763 2026-01-01 2026-09-30 0001014763 AIMD:CommonStockParValue0.01PerShareMember 2026-01-01 2026-09-30 0001014763 AIMD:WarrantsToPurchaseCommonStockMember 2026-01-01 2026-09-30 0001014763 2026-11-16 0001014763 2026-09-30 0001014763 2025-12-31 0001014763 2026-07-01 2026-09-30 0001014763 2025-07-01 2025-09-30 0001014763 2025-01-01 2025-09-30 0001014763 us-gaap:RelatedPartyMember 2026-07-01 2026-09-30 0001014763 us-gaap:RelatedPartyMember 2026-01-01 2026-09-30 0001014763 us-gaap:RelatedPartyMember 2025-07-01 2025-09-30 0001014763 us-gaap:RelatedPartyMember 2025-01-01 2025-09-30 0001014763 us-gaap:PreferredStockMember 2026-06-30 0001014763 us-gaap:CommonStockMember 2026-06-30 0001014763 AIMD:CommonStockToBeIssuedMember 2026-06-30 0001014763 us-gaap:TreasuryStockCommonMember 2026-06-30 0001014763 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001014763 us-gaap:RetainedEarningsMember 2026-06-30 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-06-30 0001014763 2026-06-30 0001014763 us-gaap:PreferredStockMember 2025-06-30 0001014763 us-gaap:CommonStockMember 2025-06-30 0001014763 AIMD:CommonStockToBeIssuedMember 2025-06-30 0001014763 us-gaap:TreasuryStockCommonMember 2025-06-30 0001014763 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001014763 us-gaap:RetainedEarningsMember 2025-06-30 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001014763 2025-06-30 0001014763 us-gaap:PreferredStockMember 2025-12-31 0001014763 us-gaap:CommonStockMember 2025-12-31 0001014763 AIMD:CommonStockToBeIssuedMember 2025-12-31 0001014763 us-gaap:TreasuryStockCommonMember 2025-12-31 0001014763 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001014763 us-gaap:RetainedEarningsMember 2025-12-31 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001014763 us-gaap:PreferredStockMember 2024-12-31 0001014763 us-gaap:CommonStockMember 2024-12-31 0001014763 AIMD:CommonStockToBeIssuedMember 2024-12-31 0001014763 us-gaap:TreasuryStockCommonMember 2024-12-31 0001014763 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001014763 us-gaap:RetainedEarningsMember 2024-12-31 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001014763 2024-12-31 0001014763 us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001014763 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001014763 AIMD:CommonStockToBeIssuedMember 2026-07-01 2026-09-30 0001014763 us-gaap:TreasuryStockCommonMember 2026-07-01 2026-09-30 0001014763 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001014763 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-07-01 2026-09-30 0001014763 us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001014763 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001014763 AIMD:CommonStockToBeIssuedMember 2025-07-01 2025-09-30 0001014763 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0001014763 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001014763 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0001014763 us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0001014763 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001014763 AIMD:CommonStockToBeIssuedMember 2026-01-01 2026-09-30 0001014763 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-09-30 0001014763 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001014763 us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-09-30 0001014763 us-gaap:PreferredStockMember 2025-01-01 2025-09-30 0001014763 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001014763 AIMD:CommonStockToBeIssuedMember 2025-01-01 2025-09-30 0001014763 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-09-30 0001014763 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001014763 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-09-30 0001014763 us-gaap:PreferredStockMember 2026-09-30 0001014763 us-gaap:CommonStockMember 2026-09-30 0001014763 AIMD:CommonStockToBeIssuedMember 2026-09-30 0001014763 us-gaap:TreasuryStockCommonMember 2026-09-30 0001014763 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001014763 us-gaap:RetainedEarningsMember 2026-09-30 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-09-30 0001014763 us-gaap:PreferredStockMember 2025-09-30 0001014763 us-gaap:CommonStockMember 2025-09-30 0001014763 AIMD:CommonStockToBeIssuedMember 2025-09-30 0001014763 us-gaap:TreasuryStockCommonMember 2025-09-30 0001014763 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001014763 us-gaap:RetainedEarningsMember 2025-09-30 0001014763 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0001014763 2025-09-30 0001014763 us-gaap:CommonStockMember 2022-05-16 2022-05-16 0001014763 2023-11-27 0001014763 us-gaap:CommonStockMember 2023-12-14 2023-12-14 0001014763 2025-05-16 0001014763 us-gaap:CommonStockMember 2025-06-30 2025-06-30 0001014763 AIMD:ATMAgreementMember 2024-05-01 2024-05-31 0001014763 AIMD:ATMAgreementMember srt:MaximumMember 2024-05-01 2024-05-31 0001014763 AIMD:ATMAgreementMember 2024-07-11 2024-07-11 0001014763 AIMD:SalesAgreementMember 2025-09-05 2025-09-05 0001014763 AIMD:SalesAgreementMember 2026-07-24 2026-07-24 0001014763 AIMD:ATMAgreementMember 2026-01-01 2026-09-30 0001014763 AIMD:ATMAgreementMember 2026-09-30 0001014763 us-gaap:SubsequentEventMember AIMD:IntellectualPropertyLicensingAgreementMember 2026-10-01 0001014763 us-gaap:SubsequentEventMember AIMD:IntellectualPropertyLicensingAgreementMember AIMD:SemiConductorMember 2026-10-01 0001014763 AIMD:MarchTwoThousandTwentyFiveConvertibleNotesMember 2026-09-30 0001014763 AIMD:MarchTwoThousandTwentyFiveConvertibleNotesMember 2025-12-31 0001014763 AIMD:MayTwoThousandTwentySevenConvertibleNotesMember 2026-09-30 0001014763 AIMD:MayTwoThousandTwentySevenConvertibleNotesMember 2025-12-31 0001014763 AIMD:ASENoteMember AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember 2023-03-13 2023-03-13 0001014763 AIMD:ASENoteTrancheOneMember AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember 2023-03-13 2023-03-13 0001014763 AIMD:ASENoteTrancheTwoMember AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember 2023-03-13 2023-03-13 0001014763 AIMD:ASENoteTrancheThreeMember AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember 2023-03-13 2023-03-13 0001014763 AIMD:ASENoteMember AIMD:ConvertibleNoteAmendmentMember 2025-03-10 2025-03-10 0001014763 AIMD:ASENoteMember AIMD:ConvertibleNoteAmendmentMember 2025-03-10 0001014763 AIMD:ASENoteMember AIMD:ConvertibleNoteAmendmentMember 2025-06-30 2025-06-30 0001014763 AIMD:LeeNoteMember AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember 2023-03-13 0001014763 AIMD:LeeNoteMember AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember AIMD:BeforeMaturityDateMember srt:MinimumMember 2023-03-13 0001014763 AIMD:LeeNoteMember AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember srt:MaximumMember 2023-03-13 0001014763 AIMD:LeeNoteMember AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember 2026-07-01 2026-09-30 0001014763 AIMD:LeeNoteMember AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember 2026-01-01 2026-09-30 0001014763 AIMD:LeeNoteMember AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember 2025-07-01 2025-09-30 0001014763 AIMD:LeeNoteMember AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember 2025-01-01 2025-09-30 0001014763 AIMD:LeeNoteMember AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember 2026-09-30 0001014763 AIMD:LeeNoteMember AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember 2025-12-31 0001014763 AIMD:ConvertibleNoteAndWarrantPurchaseAgreementMember 2024-05-03 2024-05-03 0001014763 AIMD:ConvertibleNoteAndWarrantPurchaseAgreementMember 2024-05-03 0001014763 AIMD:ConvertibleNoteAndWarrantPurchaseAgreementMember us-gaap:CommonStockMember srt:MaximumMember 2024-05-03 0001014763 AIMD:ConvertibleNoteAndWarrantPurchaseAgreementMember us-gaap:CommonStockMember 2024-05-03 0001014763 AIMD:ConvertibleNoteAndWarrantPurchaseAgreementMember 2026-09-30 0001014763 AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember AIMD:MarchTwoThousandTwentySixConvertibleNotesMember 2026-03-27 0001014763 AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember AIMD:MarchTwoThousandTwentySixConvertibleNotesMember 2026-03-27 2026-03-27 0001014763 AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember AIMD:MarchTwoThousandTwentySixConvertibleNotesMember 2026-07-07 0001014763 AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember AIMD:MarchTwoThousandTwentySixConvertibleNotesMember 2026-09-30 0001014763 AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember 2026-07-01 2026-09-30 0001014763 AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember 2026-01-01 2026-09-30 0001014763 AIMD:ConvertiblePromissoryNotePurchaseAgreementsMember 2026-09-30 0001014763 2025-06-30 2025-06-30 0001014763 2023-11-26 0001014763 AIMD:PlacementAgentWarrantMember 2026-09-30 0001014763 AIMD:PlacementAgentWarrantMember 2026-01-01 2026-09-30 0001014763 AIMD:PrivateWarrantMember 2026-09-30 0001014763 AIMD:LindWarrantMember 2026-09-30 0001014763 AIMD:LindWarrantMember 2025-12-31 0001014763 AIMD:PublicWarrantMember 2026-09-30 0001014763 AIMD:PublicWarrantMember 2025-12-31 0001014763 AIMD:RepresentativeWarrantMember 2026-09-30 0001014763 AIMD:RepresentativeWarrantMember 2025-12-31 0001014763 AIMD:PlacementAgentWarrantMember 2025-12-31 0001014763 AIMD:ASEWarrantMember 2026-09-30 0001014763 AIMD:ASEWarrantMember 2025-12-31 0001014763 AIMD:LindWarrantMember srt:MinimumMember 2026-09-30 0001014763 AIMD:LindWarrantMember srt:MaximumMember 2026-09-30 0001014763 2023-06-14 0001014763 2024-07-19 0001014763 2025-04-04 0001014763 AIMD:TwoThousandTwentyThreeStockIncentivePlanMember 2026-02-13 0001014763 AIMD:TwoThousandTwentyThreeStockIncentivePlanMember 2026-09-30 0001014763 us-gaap:WarrantMember 2026-07-01 2026-09-30 0001014763 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001014763 us-gaap:WarrantMember 2025-07-01 2025-09-30 0001014763 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2026-03-31 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2025-03-31 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2026-04-01 2026-06-30 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2025-04-01 2025-06-30 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2026-06-30 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2025-06-30 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2026-07-01 2026-09-30 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2025-07-01 2025-09-30 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2026-09-30 0001014763 us-gaap:RestrictedStockUnitsRSUMember 2025-09-30 0001014763 AIMD:StockOptionsAndRestrictedStockUnitsMember 2026-07-01 2026-09-30 0001014763 AIMD:StockOptionsAndRestrictedStockUnitsMember 2025-07-01 2025-09-30 0001014763 AIMD:StockOptionsAndRestrictedStockUnitsMember 2026-01-01 2026-09-30 0001014763 AIMD:StockOptionsAndRestrictedStockUnitsMember 2025-01-01 2025-09-30 0001014763 us-gaap:WarrantMember 2026-07-01 2026-09-30 0001014763 us-gaap:WarrantMember 2025-07-01 2025-09-30 0001014763 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001014763 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001014763 us-gaap:ConvertibleDebtSecuritiesMember 2026-07-01 2026-09-30 0001014763 us-gaap:ConvertibleDebtSecuritiesMember 2025-07-01 2025-09-30 0001014763 us-gaap:ConvertibleDebtSecuritiesMember 2026-01-01 2026-09-30 0001014763 us-gaap:ConvertibleDebtSecuritiesMember 2025-01-01 2025-09-30 0001014763 AIMD:ProductCoDevelopmentAgreementMember 2026-07-01 2026-09-30 0001014763 AIMD:ProductCoDevelopmentAgreementMember 2026-01-01 2026-09-30 0001014763 AIMD:ProductCoDevelopmentAgreementMember 2025-07-01 2025-09-30 0001014763 AIMD:ProductCoDevelopmentAgreementMember 2025-01-01 2025-09-30 0001014763 AIMD:ProductCoDevelopmentAgreementMember us-gaap:PatentsMember 2026-07-01 2026-09-30 0001014763 AIMD:ProductCoDevelopmentAgreementMember us-gaap:PatentsMember 2026-01-01 2026-09-30 0001014763 AIMD:ProductCoDevelopmentAgreementMember us-gaap:PatentsMember 2025-07-01 2025-09-30 0001014763 AIMD:ProductCoDevelopmentAgreementMember us-gaap:PatentsMember 2025-01-01 2025-09-30 0001014763 AIMD:ProductCoDevelopmentAgreementMember 2025-01-01 2025-12-31 0001014763 AIMD:ManufacturingServiceAgreementMember 2026-09-30 0001014763 AIMD:ManufacturingServiceAgreementMember 2026-01-01 2026-09-30 0001014763 AIMD:ManufacturingServiceAgreementMember 2025-01-01 2025-12-31 0001014763 2026-06-01 0001014763 2026-06-01 2026-06-01 0001014763 us-gaap:SubsequentEventMember AIMD:SalesAgreementMember 2026-11-12 2026-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:TWD AIMD:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from____to____

 

Commission File No. 001-41461

 

AINOS, INC.

(Exact name of registrant as specified in its charter)

 

texas   75-1974352
(State or other jurisdiction of
incorporation or organization)
 

(IRS Employer

Identification No.)

 

3050 Post Oak Blvd, Suite 510-T80, Houston, TX 77056 (281)898-6586

(Address and telephone number, including area code, of registrant’s principal executive offices)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   AIMD   The Nasdaq Stock Market LLC
Warrants to purchase Common Stock   AIMDW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐ Yes ☒ No

 

As of November 16, 2026, there were issued 8,725,590 shares and outstanding 7,565,590 shares of the registrant’s common stock, par value $0.01, which is the only class of common or voting stock of the registrant.

 

 

 

 
 

 

AINOS, INC.

INDEX

 

     

PAGE

NO.

PART I: FINANCIAL INFORMATION   3
ITEM 1. Financial Statements   3
  Condensed Consolidated Balance Sheets – September 30, 2026 (unaudited) and December 31, 2025   3
  Condensed Consolidated Statements of Operations – Three and Nine Months Ended September 30, 2026 and 2025 (unaudited)   4
  Condensed Consolidated Statements of Comprehensive Loss – Three and Nine Months Ended September 30, 2026 and 2025 (unaudited)   5
  Condensed Consolidated Statements of Stockholders’ Equity– Three Months Ended September 30, 2026 and 2025 (unaudited)   6
  Condensed Consolidated Statements of Stockholders’ Equity– Nine Months Ended September 30, 2026 and 2025 (unaudited)   7
  Condensed Consolidated Statements of Cash Flows – Nine Months Ended September 30, 2026 and 2025 (unaudited)   8
  Notes to Condensed Consolidated Financial Statements (unaudited)   9
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   20
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk   27
ITEM 4. Controls and Procedures   27
       
PART II: OTHER INFORMATION   27
ITEM 1. Legal Proceedings   27
ITEM 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities   29
ITEM 3. Defaults Upon Senior Securities   29
ITEM 4. Mine Safety Disclosures   29
ITEM 5. Other Information   29
ITEM 6. Exhibits   30
Signatures   31

 

2
 

 

PART I - FINANCIAL INFORMATION

 

ITEM 1. Financial Statements

 

Ainos, Inc.

Condensed Consolidated Balance Sheets

 

   September 30,   December 31, 
   2026   2025 
   (Unaudited)     
Assets          
Current assets:          
Cash and cash equivalents  $660,916   $417,353 
Accounts receivable   643,064    22 
Inventory, net   243,729    295,565 
Other current assets   522,120    425,859 
Total current assets   2,069,829    1,138,799 
Intangible assets, net   15,843,468    19,226,003 
Property and equipment, net   264,923    343,281 
Other assets   137,717    163,025 
Total assets  $18,315,937   $20,871,108 
           
Liabilities and Stockholders’ Equity          
Current liabilities:          
Contract liabilities  $350,000   $350,000 
Convertible notes payable   11,000,000    - 
Loan payable   2,812,940    - 
Accrued expenses and other current liabilities   2,431,960    728,683 
Total current liabilities   16,594,900    1,078,683 
Convertible notes payable - noncurrent   -    11,000,000 
Other long-term liabilities   -    1,229,843 
Total liabilities   16,594,900    13,308,526 
Commitments and contingencies   -    - 
Stockholders’ equity:          
Preferred stock, $0.01 par value; 50,000,000 shares authorized; none issued and outstanding as of September 30, 2026 and December 31, 2025   -    - 
Common stock, $0.01 par value; 300,000,000 shares authorized as of September 30, 2026 and December 31, 2025, 8,714,324 and 6,982,675 shares issued and 7,554,324 and 5,822,675 shares outstanding as of September 30, 2026, and December 31, 2025, respectively   87,143    69,827 
Common Shares to be issued are 2,801 and nil shares as of September 30, 2026 and December 31, 2025, respectively   28    - 
Treasury stock, at cost (1,160,000 shares held as of September 30, 2026 and December 31, 2025)   (1,972,000)   (1,972,000)
Additional paid-in capital   80,309,746    77,234,374 
Accumulated deficit   (76,460,933)   (67,520,328)
Accumulated other comprehensive loss   (242,947)   (249,291)
Total stockholders’ equity   1,721,037    7,562,582 
Total liabilities and stockholders’ equity  $18,315,937   $20,871,108 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3
 

 

Ainos, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

 

   2026   2025   2026   2025 
   Three months ended September 30,   Nine months ended September 30, 
   2026   2025   2026   2025 
                 
Revenues  $642,889   $2,167   $643,202   $113,037 
Cost of revenues   (106,623)   (477)   (107,439)   (19,647)
Gross profit   536,266    1,690    535,763    93,390 
Operating expenses:                    
Research and development (including amounts of related party of $231,867 and $681,437 for the three and nine months ended September 30, 2026, and $233,564 and $715,249 for the three and nine months ended September 30, 2025, respectively)   1,696,019    1,990,630    5,236,288    5,626,514 
Selling, general and administrative   524,919    795,253    3,666,880    4,159,627 
Total operating expenses   2,220,938    2,785,883    8,903,168    9,786,141 
Loss from operations   (1,684,672)   (2,784,193)   (8,367,405)   (9,692,751)
                     
Non-operating (expenses) income, net:                    
Interest expense   (204,763)   (176,584)   (581,801)   (534,986)
Other income, net   3,361    29,075    8,601    (74,977)
Total non-operating expenses, net   (201,402)   (147,509)   (573,200)   (609,963)
                     
Net loss before income taxes   (1,886,074)   (2,931,702)   (8,940,605)   (10,302,714)
Provision for income taxes   -    -    -    - 
Net loss  $(1,886,074)  $(2,931,702)  $(8,940,605)  $(10,302,714)
Net loss per common share - basic and diluted  $(0.25)  $(0.64)  $(1.29)  $(2.61)
Weighted-average shares used in computing net loss per common share-basic and diluted   7,427,852    4,554,359    6,943,977    3,954,762 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4
 

 

Ainos, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

 

   2026   2025   2026   2025 
   Three months ended September 30,   Nine months ended September 30, 
   2026   2025   2026   2025 
                 
Net loss  $(1,886,074)  $(2,931,702)  $(8,940,605)  $(10,302,714)
Other comprehensive loss:                     
Translation adjustment   (5,369)   (66,415)   6,344    195,046 
Comprehensive loss  $(1,891,443)  $(2,998,117)  $(8,934,261)  $(10,107,668)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5
 

 

Ainos, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

For the three months ended September 30, 2026 and 2025

(Unaudited)

 

   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Loss   Equity 
   Preferred Stock   Common Stock   Common Stock - to be issued   Treasury Stock   Additional Paid-in   Accumulated   Accumulated Other Comprehensive   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Loss   Equity 
Balance at June 30, 2026   -   $-    8,544,073   $85,441    -   $-    (1,160,000)  $(1,972,000)  $79,982,981   $(74,574,859)  $(237,578)  $3,283,985 
Issuance of common stock from at-the-market offering   -    -    150,720    1,507    2,801    28    -    -    230,655    -    -    232,190 
Issuance of common stock for consulting services   -    -    19,531    195    -    -    -    -    74,805    -    -    75,000 
Share-based compensation   -    -    -    -    -    -    -    -    21,305    -    -    21,305 
Net loss   -    -    -    -    -    -    -    -    -    (1,886,074)   -    (1,886,074)
Translation adjustment   -    -    -    -    -    -    -    -    -    -    (5,369)   (5,369)
Balance at Sep 30, 2026         -   $       -    8,714,324   $87,143    2,801   $28    (1,160,000)  $(1,972,000)  $80,309,746   $(76,460,933)  $(242,947)  $1,721,037 
                                                             
Balance at June 30, 2025   -   $-    4,267,990   $42,680    -   $-    -   $-   $71,668,502   $(60,120,328)  $(148,068)  $11,442,786 
Issuance of stock to settle vested RSUs   -    -    93,792    938    -    -    -    -    (938)   -    -    - 
Issuance of common stock from at-the-market offering   -    -    412,484    4,125    12,651    127    -    -    1,172,672    -    -    1,176,924 
Issuance of common stock paying consulting fee   -    -    19,531    195    -    -    -    -    74,805    -    -    75,000 
Share-based compensation   -    -    -    -    -    -    -    -    348,356    -    -    348,356 
Net loss   -    -    -    -    -    -    -    -    -    (2,931,702)   -    (2,931,702)
Translation adjustment   -    -    -    -    -    -    -    -    -    -    (66,415)   (66,415)
Balance at Sep 30, 2025   -   $-    4,793,797   $47,938    12,651   $127    -   $-   $73,263,397   $(63,052,030)  $(214,483)  $10,044,949 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6
 

 

Ainos, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

For the nine months ended September 30, 2026 and 2025

(Unaudited)

 

   Preferred Stock   Common Stock   Common Stock - to be issued   Treasury Stock   Additional Paid-in   Accumulated   Accumulated Other Comprehensive   Total Stockholders’ Equity 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Loss   (Deficit) 
Balance at December 31, 2025   -   $-    6,982,675   $69,827    -   $-    (1,160,000)  $(1,972,000)  $77,234,374   $(67,520,328)  $(249,291)  $7,562,582 
Issuance of stock to settle vested RSUs   -    -    1,239,000    12,390    -    -    -    -    (12,390)   -    -    - 
Issuance of common stock from at-the-market offering   -    -    434,056    4,340    2,801    28    -    -    829,422    -    -    833,790 
Issuance of common stock for consulting services   -    -    58,593    586    -    -    -    -    224,414    -    -    225,000 
Share-based compensation   -    -    -    -    -    -    -    -    2,033,926    -    -    2,033,926 
Net loss   -    -    -    -    -    -    -    -    -    (8,940,605)   -    (8,940,605)
Translation adjustment      -              -    -    -    -    -    -    -    -    -    6,344    6,344 
Balance at Sep 30, 2026   -   $-    8,714,324   $87,143    2,801   $28    (1,160,000)  $(1,972,000)  $80,309,746   $(76,460,933)  $(242,947)  $1,721,037 
                                                             
Balance at December 31, 2024   -   $-    3,085,477   $30,854    -   $-    -   $-   $68,644,301   $(52,749,316)  $(409,529)  $15,516,310 
Issuance of stock to settle vested RSUs   -    -    634,966    6,350    -    -    -    -    (6,350)   -    -    - 
Issuance of stock to special stock bonus   -    -    350,500    3,505    -    -    -    -    858,725    -    -    862,230 
Issuance of common stock from at-the-market offering   -    -    674,867    6,749    12,651    127    -    -    1,889,406    -    -    1,896,282 
Issuance of common stock paying consulting fee   -    -    48,086    481    -    -    -    -    149,519    -    -    150,000 
Fractional shares paid out in cash for the reverse stock split   -    -    (99)   (1)   -    -    -    -    (259)   -    -    (260)
Share-based compensation   -    -    -    -    -    -    -    -    1,728,055    -    -    1,728,055 
Net loss   -    -    -    -    -    -    -    -    -    (10,302,714)        (10,302,714)
Translation adjustment   -    -    -    -    -    -    -    -    -    -    195,046    195,046 
Balance at Sep 30, 2025   -   $-    4,793,797   $47,938    12,651   $127    -   $-   $73,263,397   $(63,052,030)  $(214,483)  $10,044,949 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

7
 

 

Ainos, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

   2026   2025 
   Nine months ended September 30, 
   2026   2025 
Cash flows from operating activities:          
Net loss  $(8,940,605)  $(10,302,714)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   3,553,809    3,578,083 
Share-based compensation expense   2,033,926    1,728,055 
Stock issued for special stock bonus   -    862,230 
Issuance of common stock for paying consulting fee   225,000    150,000 
Changes in operating assets and liabilities:          
Accounts receivable   (643,042)   (6)
Inventory   (37,608)   (23,127)
Other current assets   (94,664)   (81,289)
Accrued expenses and other current and long-term liabilities   473,507    329,089 
Net cash used in operating activities   (3,429,677)   (3,759,679)
Cash flows from investing activities:          
Purchase of property and equipment   (11,433)   (36,090)
Proceeds from disposal of equipment   1,758    - 
Decrease in refundable deposits and other assets   29,239    22,978 
Net cash provided by (used in) investing activities   19,564    (13,112)
Cash flows from financing activities:          
Proceeds from Loan agreement   2,812,940    - 
Proceeds from at-the-market offering, net of issuance costs   830,435    1,852,895 
Repayment of convertible notes payable   -    (1,000,000)
Fractional shares paid out in cash for the reverse stock split   -    (260)
Net cash provided by financing activities   3,643,375    852,635 
Effect from foreign currency exchange   10,301    155,454 
Net increase (decrease) in cash and cash equivalents   243,563    (2,764,702)
Cash and cash equivalents at beginning of period   417,353    3,892,919 
Cash and cash equivalents at end of period  $660,916   $1,128,217 
Noncash financing and investing activities:          
Uncollected proceeds from at the market offering, net of issuance costs  $3,355    43,387 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

8
 

 

Ainos, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

1. Description of Business

 

Organization and Business

 

Ainos, Inc. (the “Company”) was incorporated in the State of Texas in 1984. The Company is a dual-platform company engaged in the development of artificial intelligence-enabled olfactory sensing technologies and related applications, which support our broader vision of Chemical Intelligence, as well as the development of immune therapeutics.

 

Our core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models to digitize scent and volatile organic compound (“VOC”) signals into Smell ID, a machine-readable data format. AI Nose was initially developed in healthcare-related settings, including point-of-care testing (“POCT”). These early healthcare applications shaped the platform’s sensor architecture, data models, and system calibration.

 

Building on this foundation, we are expanding the application of AI Nose into industrial environments, where we believe real-time environmental sensing, anomaly detection, and operational monitoring are important. Current and planned use cases include applications across semiconductor manufacturing, robotics, healthcare infrastructure and smart manufacturing settings. We believe the underlying scent digitization architecture of AI Nose is adaptable across a range of industrial and non-industrial verticals, and we continue to evaluate additional application opportunities based on partner engagement and deployment experience.

 

We are advancing the AI Nose platform through partner-led deployments, with a strategy focused on platform scalability, data-driven performance improvement, and integration into existing industrial ecosystems. Our approach emphasizes expanding the role of scent and airborne chemicals as a machine-readable data modalities alongside vision and sound, while maintaining flexibility to address diverse operational requirements.

 

Separately, we continue to pursue the development and commercialization of VELDONA®, our low-dose oral interferon platform, targeting selected rare, autoimmune, and infectious disease indications, primarily through licensing arrangements and collaborations with third-party partners. Our VELDONA® priority programs include candidates for the treatment of oral warts in HIV-positive patients, Sjögren’s syndrome, and feline chronic gingivostomatitis (“FCGS”). We have conducted research and development activities related to VELDONA® since our inception.

 

Reverse Stock Splits

 

In connection with the Offering, the Company’s board of directors on April 29, 2022 and its shareholders on May 16, 2022 approved a 1-for-15 reverse stock split of the Company’s common stock that became effective on August 9, 2022. Further, to comply with Nasdaq’s minimum $1.00 per share continued listing rules, the Company filed a Certificate of Amendment to its Restated Certificate of Formation on November 27, 2023, to apply for another reverse stock split of the Company’s common stock at a ratio of 1-for-5 which was effectuated on December 14, 2023 after receiving required approvals. In addition, to comply with Nasdaq’s minimum $1.00 per share continued listing rules, the Company filed a Certificate of Amendment to its Restated Certificate of Formation on May 16, 2025, the Board approved for another reverse stock split of the Company’s common stock at a ratio of 1-for-5 which was effectuated on June 30, 2025 after receiving required approvals.

 

The par value of $0.01 and authorized shares of the Company’s common stock remain the same and were not adjusted as a result of the reverse stock splits. All issued and outstanding common stock, restricted stock units (RSUs), outstanding convertible notes, warrants and options to purchase common stock and per share amounts contained in the financial statements have been retroactively adjusted to give effect to the reverse stock splits for all periods presented.

 

9
 

 

At-the-Market Offering Agreement

 

On May 31, 2024, the Company entered into an At-the-Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”), pursuant to which the Company may issue and sell, from time to time, shares of its Common Stock, depending on market demand, with the Agent acting as the sales agent or principal (the “ATM Offering”). Sales of the Common Stock may be made by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended (the “Securities Act”), including, without limitation, sales made directly on or through the Nasdaq Capital Market. The Agent will use its commercially reasonable efforts to sell the Shares requested by the Company to be sold on its behalf, consistent with the Agent’s normal trading and sales practices, under the terms and subject to the conditions set forth in the ATM Agreement. The Company has no obligation to sell any of the Shares. The Company may instruct the Agent not to sell the Shares if the sales cannot be effected at or above the price designated by the Company from time to time and the Company may at any time suspend sales pursuant to the ATM Agreement.

 

The Company will pay the Agent placement fee of 3.0% of the gross sales price of the Shares sold by the Agent under the ATM Agreement. The Company has also agreed to reimburse the Agent for the fees and disbursements of its counsel, payable upon execution of the Sales Agreement, in an amount not to exceed $35,000 in addition to certain ongoing disbursements of its legal counsel up to $2,500 per calendar quarter. In addition, the Company has agreed to provide customary indemnification rights to the Agent.

 

The aggregate market value of Shares eligible for sale in the ATM Offering and under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3, to the extent required under such instruction. The prospectus supplement filed with the SEC on July 11, 2024, is offering Shares having an aggregate offering price of $1,840,350.

 

The Company intends to use the net proceeds from the offering to fund the continued development of its product candidate and for general corporate purposes and working capital. The precise amount and timing of the application of these proceeds will depend upon a number of factors, such as the timing and progress of our research and development efforts, our funding requirements and the availability and costs of other funds.

 

On September 5, 2025, the Company filed a prospectus supplement to amend the Prospectus to update the amount of shares the Company is eligible to sell pursuant to such prospectus. The Company increased the amount of shares of Common Stock it may offer and sell under the Sales Agreement to an aggregate offering price of up to $874,496 from time to time through Wainwright. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding one-third of our public float in any 12-month calendar period so long as our public float remains below $75.0 million.

 

On July 24, 2026, the Company filed a prospectus supplement to amend the Prospectus to update the amount of shares the Company is eligible to sell pursuant to such prospectus. The Company increased the amount of shares of Common Stock it may offer and sell under the Sales Agreement to an aggregate offering price of up to$1,346,165 from time to time through Wainwright. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding one-third of our public float in any 12-month calendar period so long as our public float remains below $75.0 million.

 

For the first nine months of the year 2026, the Company sold 436,857 shares of common stock under the ATM facility and received $830,435 in net proceeds after deducting commissions and expenses. As of September 30, 2026, the Company sold an aggregate of 1,171,071 shares of the Company’s common stock under the ATM facility and received $2,839,156 in net proceeds after deducting commissions and expenses.

 

10
 

 

2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (the “GAAP”) and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s audited financial statements as of and for the year ended December 31, 2025 contained in the Annual Report on Form 10-K filed with the SEC on March 30, 2026.

 

In the opinion of management, the accompanying condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods. The results for the nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for any subsequent quarter, the year ending December 31, 2026, or any other period.

 

There have been no material changes to the Company’s significant accounting policies as described in the audited financial statements as of December 31, 2025.

 

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosures as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on various factors, including historical experience, and on various other assumptions that are believed to be reasonable under the circumstances, when these carrying values are not readily available from other sources. Significant items subject to estimates and assumptions include useful lives of property and equipment, valuation of stock option, warrants and convertible notes measured at fair value, and impairment testing of intangible assets. Actual results may differ from these estimates.

 

Liquidity

 

As of September 30, 2026, the Company had cash and cash equivalents of $660,916. The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity, and/or debt financing arrangements. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company’s business, results of operations, and financial condition could be materially adversely impacted.

 

Subsequent to September 30, 2026, the Company received $600,000 in outstanding accounts receivable related to its VELDONA® intellectual property licensing agreement and $350,000 associated with its AI Nose commercialization activities in semiconductor manufacturing. These collections, totaling $950,000, strengthened the Company’s liquidity position and increased its cash resources compared to September 30, 2026. Management believes these additional resources will support the Company’s ongoing operating activities, working capital requirements, and planned business initiatives.

 

On May 31, 2024, the Company entered into an At-the-Market Offering Agreement, or sales agreement, with H.C. Wainwright & Co., LLC or Wainwright, pursuant to which the Company may issue and sell, from time to time, shares of its common stock, the aggregate market value of Shares eligible for sale in the Offering and under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3, to the extent required under such instruction. The prospectus supplement filed with the SEC on July 11, 2024, is offering Shares having an aggregate offering price of $1,840,350.

 

On September 5, 2025, the Company filed a prospectus supplement to amend the Prospectus to update the amount of shares the Company is eligible to sell pursuant to such prospectus. The Company increased the amount of shares of Common Stock it may offer and sell under the Sales Agreement to an aggregate offering price of up to $874,496 from time to time through Wainwright. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding one-third of our public float in any 12-month calendar period so long as our public float remains below $75.0 million.

 

11
 

 

On July 24, 2026, the Company filed a prospectus supplement to amend the Prospectus to update the amount of shares the Company is eligible to sell pursuant to such prospectus. The Company increased the amount of shares of Common Stock it may offer and sell under the Sales Agreement to an aggregate offering price of up to$1,346,165 from time to time through Wainwright. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding one-third of our public float in any 12-month calendar period so long as our public float remains below $75.0 million.

 

For the nine months ended September 30, 2026, the Company sold 436,857 shares of common stock under the ATM facility and received $830,435 in net proceeds after deducting commissions and expenses. As of September 30, 2026, the Company sold 1,171,071 shares of common stock under At-the-Market Offering Agreement, resulting in net proceeds of approximately $2,839,156.

 

For the nine months ended September 30, 2026, the Company generated a net loss of $8,940,605. The Company expects to continue incurring development expenses for the next twelve months as the Company advances its product development plans.

 

The financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net operating losses since inception and has an accumulated deficit as of September 30, 2026 of $76,460,933 and expects to incur additional losses and negative operating cash flows for at least the next twelve months. The Company’s ability to meet its obligations is dependent upon its ability to generate sufficient cash flows from operations and future financing transactions. Although management expects the Company will continue as a going concern, there is no assurance that management’s plans will be successful since the availability and amount of such funding is not certain. Accordingly, substantial doubt exists about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

Segments

 

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (the “CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the Company’s CODM. The CODM reviews financial information prepared on the basis of accounting policy disclosed in its annual financial statement for purposes of making operating decisions, allocating resources, and evaluating financial performance of the Company. As such, the Company has determined that it operates as one operating segment.

 

Impairment of Intangible Assets

 

The Company reviews its definite-lived intangibles and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be fully recoverable. When such events occur, management determines whether there has been impairment by comparing the anticipated undiscounted future net cash flows to the carrying value of the asset or asset group. If impairment exists, the assets are written down to their estimated fair value. No impairment of definite-lived intangible and long-lived assets was recorded for the three and nine months ended September 30, 2026 and 2025.

 

Fair Value Option

 

ASC 825-10, Financial Instruments, provides a fair value option (the “FVO”) election that allows companies an irrevocable election to use fair value as the initial and subsequent accounting measurement attribute for certain financial assets and liabilities. ASC 825-10 permits entities to elect to measure eligible financial assets and liabilities at fair value on an ongoing basis. Unrealized gains and losses on items for which the FVO has been elected are reported in earnings, except for the effect of changes in own credit, which are recognized in other comprehensive income/loss. The decision to elect the FVO is determined on an instrument-by-instrument basis, must be applied to an entire instrument and is irrevocable once elected. Assets and liabilities measured at fair value pursuant to ASC 825-10 are required to be reported separately from those instruments measured using another accounting method.

 

12
 

 

Recent Accounting Pronouncements Adopted

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07, which is applicable to entities with a single reportable segment, will primarily require enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 31, 2024, with early adoption permitted. The Company adopted the ASU for the fiscal year ended December 31, 2025 on a retrospective basis for all prior periods presented in the financial statements.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company adopted the ASU for the fiscal year ended December 31, 2025 on a retrospective basis for all prior periods presented in the financial statements.

 

Accounting Standards Issued but Not Yet Adopted

 

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its financial statements and disclosures.

 

In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) (“ASU 2025-06”). ASU 2025-06 updates the accounting guidance for internal-use software by eliminating references to software development project stages, thereby requiring companies to start capitalizing software costs when (i) management has authorized and committed to funding the project, and (ii) it is probable the project will be completed and the software will be used as intended. ASU 2025-06 is effective for annual periods beginning after December 15, 2027, with early adoption permitted. Amendments can be applied either (i) prospectively, (ii) through a modified transition approach based on the status projects and whether software costs were capitalized before the date of adoption, or (iii) retrospectively. The Company is currently evaluating the impact of ASU 2025-06 on the Company’s financial condition and results of operations.

 

In December 2025, the FASB issued ASU 2025-10 to provide specific authoritative guidance about the recognition, measurement, and presentation of a grant received by a business entity from a government. The amendments in this guidance require that a government grant received by a business entity should not be recognized until (1) it is probable that a business entity will comply with the conditions attached to the grant and the grant will be received and (2) a business entity meets the recognition guidance for a grant related to an asset or a grant related to income. Adoption of this standard is required using either a modified prospective, modified retrospective, or a retrospective approach. This standard is effective for the Company for both interim and annual reporting for the year ended December 31, 2029. The Company is currently evaluating the impact of ASU 2025-10 on the Company’s financial condition and results of operations.

 

The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated financial position, statements of operations and cash flows.

 

13
 

 

3. Cash and Cash Equivalents

 

As of September 30, 2026 and December 31, 2025, cash and cash equivalents consisted of cash on hand and cash in bank which is potentially subject to concentration of credit risk. Such balance is maintained at financial institutions that management determines to be of high credit quality. Cash accounts at each institution are insured by the Federal Deposit Insurance Corporation (FDIC) in the U.S.A or Central Deposit Insurance Corporation in Taiwan up to certain limits. At times, such deposits may be in excess of the insurance limit. Accounts are guaranteed by the FDIC up to $250,000. As of September 30, 2026 and December 31, 2025, the Company had approximately nil in excess of FDIC insured limits. The Company maintains cash in state-owned banks in Taiwan. In Taiwan, the insurance coverage of each bank is NTD$3,000,000 (approximately US$94,200). As of September 30, 2026 and December 31, 2025, the Company had $235,900 and $242,000, respectively, of cash in excess of the insured amount. The Company has not experienced any losses in such accounts.

 

4. Inventory

 

Inventory stated at cost, net of reserve, consisted of the following:

 

   September 30,   December 31, 
   2026   2025 
Raw materials  $152,329   $118,329 
Work in process   65,066    108,278 
Finished goods   26,334    68,958 
Total  $243,729   $295,565 

 

5. Convertible Notes Payable and Loan Payable

 

As of September 30, 2026 and December 31, 2025, the respective notes payable were as follows:

 

  

September 30,

2026

  

December 31,

2025

 
March 2025 Convertible Notes – noncurrent (ASE Note)  $-   $2,000,000 
March 2025 Convertible Notes – current (ASE Note)   2,000,000    - 
May 2027 Convertible Notes – current (ASE Note)   9,000,000    - 
May 2027 Convertible Notes – noncurrent (ASE Note)   -    9,000,000 
Convertible Notes payable  $11,000,000   $11,000,000 

 

March 2025 Convertible Notes

 

On March 13, 2023, the Company entered into convertible promissory note agreement with ASE Test, Inc. (the “March 2025 Convertible Note). Pursuant to the agreement, ASE Test, Inc. (“ASE Test”), committed to pay a total aggregate amount of $2,000,000 to the Company in exchange for convertible promissory note in three tranches in the amounts of $1,000,000 (the “First Tranche”), $500,000 (the “Second Tranche”), and $500,000 (the “Third Tranche”) conditioned, among other things, on the Company achieving certain business milestones. The Company received the full amount of the payment in September 2023.

 

On March 10, 2025, the Company entered into an amendment to the Convertible Note (the “ASE Convertible Note Amendment”) with ASE Test to (1) extend the maturity date to March 12, 2027, and (2) change the conversion price from $37.50 per share (adjusted for the 1-for-5 reverse stock split of the Company’s common stock on December 14, 2023 and another adjusted for the 1-for-5 reverse stock split of the Company’s common stock on June 30, 2025) to a price of the lower of (a) $37.50 per share and (b) the higher of (x) the average closing price per share of Common Stock for the period of thirty (30) trading days prior to the day when the noteholder exercises the conversion right or (y) $22.50.

 

14
 

 

The March 2025 Convertible Note bear interest at the rate of 6% compounded interest per annum. At any time after the issuance and before the maturity date, the Notes are convertible into the common stock of the Company at the conversion price from $22.50 to $37.50 per share, subject to anti-dilutive adjustment as set forth in the Notes. Unless previously converted, the Company shall repay the outstanding principal amount plus all accrued and unpaid interest on the maturity date. The Notes shall be an unsecured general obligation of the Company.

 

The total interest expense of convertible notes payable and other notes payable for the three and nine months ended September 30, 2026 was $187,012 and $546,374, respectively, compared with the same period in year 2025 was $176,426 and $534,417, respectively. As of September 30, 2026 and December 31, 2025, the unpaid accrued interest expense was $1,776,217 and $1,229,843, respectively.

 

May 2027 Convertible Note

 

On May 3, 2024, The Company entered into Convertible Note and Warrant Purchase Agreement with the ASE Test, Inc. (“ASE”), for the issuance of convertible promissory notes with 6% compound interest in the aggregate principal amount of $9,000,000 (collectively the “Notes”) convertible into shares of common stock, par value $0.01 per share, of the Company, payable three (3) years from May 3, 2024 as well as the issuance of warrants for the purchase of up to 500,000 shares of common stock at a price per share of $22.50, exercisable until May 3, 2029. The full $9,000,000 principal amount under the agreement was received from ASE in May 2024.

 

March 2026 Loan agreement

 

On March 27, 2026, the Company entered into a loan agreement with ASE Test, Inc., pursuant to which ASE Test, Inc. agreed to lend the Company an aggregate principal amount of NT$90 million (the “Loan”) (approximately US$2,812,940). As of September 30, 2026 the Company received the full amount of the loan agreement.

 

The Loan bears interest at a rate of 2.5% per annum, accruing daily based on a 365-day year. The loan and the accrued interest are payable in full on the date falling exactly one (1) year after the drawdown date.

 

As previously disclosed, on March 27, 2026, the Company entered into a loan agreement with ASE Test, Inc., pursuant to which ASE Test, Inc. agreed to lend the Company an aggregate principal amount of NT$90 million (approximately US$2,812,940) (the “Loan”). The Loan was scheduled to mature on March 27, 2027. On July 10, 2026, the parties agreed to extend the maturity date of NT$62 million (approximately US$1,937,800) of the outstanding principal amount of the Loan to July 31, 2027. The maturity date of the balance of the loan, an aggregate principal amount of NT$28 million (approximately US$875,140), remains March 27, 2027.

 

The total interest expense on the loan was $14,407 and $31,988 for the three and nine months ended September 30, 2026. As of September 30, 2026 the unpaid accrued interest expense was $31,988.

 

6. Stockholders’ Equity

 

Reverse Stock Splits

 

To comply with Nasdaq’s minimum $1.00 per share continued listing rules, the Company filed a Certificate of Amendment to its Restated Certificate of Formation on May 16, 2025, to apply for reverse stock split of the Company’s common stock at a ratio of 1-for-5 which was effectuated on June 30, 2025 after receiving required approvals.

 

Preferred Stock

 

The Company increased authorized shares of preferred stock from 10,000,000 shares to 50,000,000 shares upon the filing of an amendment to the Company’s Certificate of Formation with the Secretary of State of Texas on November 27, 2023. No shares of preferred stock were issued and outstanding as of September 30, 2026 and December 31, 2025.

 

15
 

 

Common Stock

 

During the nine months ended September 30, 2026, the Company issued an additional 1,731,649 shares of common stock as a result of delivering 434,056 shares to settle for the ATM Offering, 1,239,000 shares to settle vested RSUs, 58,593 shares to compensate consultant. As of September 30, 2026, there were 8,714,324 shares of common stock legally issued and 7,554,324 shares of common stock outstanding.

 

Warrants

 

Warrants issued and outstanding in connection with financing as of September 30, 2026 and December 31, 2025 are summarized as below:

 

    September 30,     December 31,  
(In number of shares)   2026     2025  
Lind Warrant with exercise price from $10.80 to $22.50     240,388       240,388  
Public warrant with exercise price of $106.25     35,880       35,880  
Representative’s warrant with exercise price of $116.875     1,560       1,560  
Placement agent warrant with exercise price of $41.25     4,125       4,125  
ASE Warrant with exercise price of $22.50     100,000       100,000  
Total     381,953       381,953  

 

The Company issued the Lind Warrants on September 28, 2023 in connection with the private placement of the Lind Note. The Company further issued 4,125 shares of warrants with an exercise price of $41.25 per share to the placement agent as the agent fee. Each warrant has a contractual term of 5 years and can be exercised for the purchase of one share of common stock of the Company. The carrying amount of the Lind Warrant is nil after allocating proceeds to the Lind Note measured at fair value. The fair value of the placement agent warrant is estimated to be $21,479 using the Black-Scholes Model.

 

The Company issued public warrants together with common stock in connection with its underwritten public offering effective August 8, 2022. The Company further issued private warrants to Maxim Group LLC as representative of the underwriter pursuant to an underwriting agreement. Each warrant has a contractual term of 5 years, expiring on August 8, 2027, and can be exercised for the purchase of one share of common stock of the Company.

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments’ specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (the “ASC 480”), and ASC 815, Derivatives and Hedging (the “ASC 815”). The assessment considers whether the instruments are free standing financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company’s own common shares and whether the instrument holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent period end date while the instruments are outstanding. Management has concluded that the warrants issued in connection with the underwritten public offering and the private placement of Lind Note qualify for equity accounting treatment and are recorded as additional paid-in capital.

 

As of September 30, 2026, none of the warrants have been exercised nor have they expired.

 

7. Revenue

 

Revenue is recognized upon shipment of products based upon contractually stated pricing at standard payment terms within 30 to 60 days. The revenue generated by product sales is recognized at a point in time.

 

The Company generated revenue from sales of VELDONA Pet supplements in the Taiwan market through online platforms that were recognized after the expiration of right of return which was offered for a limited time. Revenue from sales through off-line distribution channels was recognized based on the amount of consideration that we expected to receive, reduced by estimates for return allowances, promotional discounts, and fees.

 

16
 

 

$350,000 of contract liabilities was recorded for the cash received in advance from customers as of September 30, 2026 and December 31, 2025.

 

The Company recognized $42,750 revenue from sales of AI Nose programs at the first three quarter of the year 2026, compared with $106,329 recognized in the same period at the first three quarter of the year 2025, offset by exchange rate fluctuation.

 

The Company has a licensing agreement granting counterparty rights to certain intellectual property, manufacturing know-how, and associated existing records relating to specified indications. Revenue for a one-time, non-refundable License Fee of $600,000 was recognized based on licensing agreement, which qualified under ASC 606-10-55-54 through 55-64.

 

Return Allowances

 

Return allowances, which reduce revenue and cost of sales, are estimated using historical experience. Liabilities for return allowances are included in “Accrued expenses and other current liabilities”.

 

Variable Consideration

 

We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods. From time to time, we offer product sales promotions such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.

 

8. Share-Based Compensation

 

2023 Stock Incentive Plan

 

The Company effectuated an amendment to its 2021 Stock Incentive Plan, now restated as the Company 2023 Stock Incentive Plan (the “2023 SIP” or “Plan”), which includes, among other things, a change in the number of reserved shares under the Plan. Under the 2023 SIP, subject to a change in capital structure or a change in control, the aggregate number of shares which may be issued or transferred pursuant to awards under the Plan will be equal to up to twenty percent (20%) of shares of outstanding common stock of the Company existing as of December 31st of the previous calendar year (the “Plan Share Reserve”). Upon the effectiveness of the 2023 SIP on June 14, 2023, the aggregate number of shares which may be issued pursuant to awards under the Plan is 174,215 shares of common stock, including shares that remained available for grant under the 2021 Stock Incentive Plan. On July 19, 2024, the Company filed Form S-8 to increase the aggregate number of shares may be issued to 189,286 shares of common stock including shares that remained available for grant under the 2021 Stock Incentive Plan. On April 4, 2025, the Company filed Form S-8 to increase the aggregate number of shares that may be issued to 617,095 shares of common stock. On February 13, 2026, the Company filed a Form S-8 to register the increased the aggregate number of shares that may be issued under the 2023 SIP to 1,396,630 shares of common stock. As of September 30, 2026, 2,376,826 shares have been granted under the 2023 SIP.

 

17
 

 

Restricted Stock Units (“RSUs”)

 

RSUs entitle the recipient to be paid out an equal number of common stock shares upon vesting. The fair value of RSUs is based on market price of the underlying stock on the date of grant. A summary of the Company’s RSUs activity and related information for the three and nine months ended September 30, 2026 and for the three and nine months ended September 30, 2025 were as follows:

 

   2026   2025 
   Number of
Shares
   Weighted-
Average
Grant Date
Fair
Value Per
Share
   Number of
Shares
   Weighted-
Average
Grant Date
Fair
Value Per
Share
 
Unvested balance at January 1   -   $-    17,966   $27.54 
RSUs granted   -   $-    -   $- 
RSUs vested   -   $-    (1,174)  $277.48 
RSUs forfeited   -   $-    -   $- 
Unvested balance at March 31   -   $-    16,792   $10.06 
RSUs granted   1,396,500   $1.61    540,000   $2.40 
RSUs vested   (1,239,000)  $1.61    (540,000)  $2.40 
RSUs forfeited   -   $-    -   $- 
Unvested balance at June 30   157,500   $1.61    16,792   $10.06 
RSUs granted   -    -    77,000    3.82 
RSUs vested   -    -    (93,792)   4.94 
RSUs forfeited   -    -    -    - 
Unvested balance at September 30   157,500   $1.61    -    - 

 

Stock Options and Warrants

 

During the three and nine months ended September 30, 2026 and 2025, no shares were granted, forfeited, expired, or exercised. As of September 30, 2026, there were 1,466 shares in the form of stock options outstanding, and 1,466 shares of the options are vested and exercisable.

 

Share-Based Compensation Expense

 

Shared-based compensation expense for the three and nine months ended September 30, 2026 was $21,305 and $2,033,926 compared to the three and nine months ended September 30, 2025 amount of $348,356 and $1,728,055, respectively.

 

As of September 30, 2026, the total unrecognized compensation cost related to outstanding RSUs, stock options and warrants was $214,439, which the Company expects to recognize over a weighted-average period of 2.54 years.

 

9. Income Taxes

 

The Company did not record a federal, state, or foreign income tax provision or benefit for the nine months ended September 30, 2026 and 2025 due to the expected loss before income taxes to be incurred for the years ended December 31, 2026 and 2025, as well as the Company’s continued maintenance of a full valuation allowance against its net deferred tax assets due to its historical deficit.

 

10. Net Loss per Common Share

 

The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders:

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Net loss attributable to common stockholders, basic and diluted  $(1,886,074) 

$

(2,931,702)  $(8,940,605)  $(10,302,714)
Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted   7,427,852    4,554,359    6,943,977    3,954,762 
Net loss per share attributable to common stockholders, basic and diluted  $(0.25)  $(0.64)  $(1.29)  $(2.61)

 

18
 

 

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive:

 

   2026   2025   2026   2025 
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Option and RSUs to purchase common stock   158,966    1,466    158,966    1,466 
Warrants to purchase common stock   381,953    383,159    381,953    383,159 
Convertible notes to purchase common stock   567,831    535,689    567,831    535,689 
Total potential shares   1,108,750    920,314    1,108,750    920,314 

 

11. Related Party Transactions

 

The following is a summary of related party transactions that met our disclosure threshold:

 

Product Co-development Agreement

 

Pursuant to a five-year Product Co-development Agreement effective on August 1, 2021 (the “Product Co-Development Agreement”) with Taiwan Carbon Nano Technology Corporation (“TCNT”), The Company entered into a five-year extension agreement effective on August 1, 2026. The development expenses incurred were $82,325 and $232,366 for the three and nine months ended September 30, 2026, compared to $84,060 and $257,732 for the three and nine months ended September 30, 2025. The fee for non-exclusive use of patents was $149,542 and $449,071 for the three and nine months ended September 30, 2026, compared to $149,504 and $ 457,517 for the three and nine months ended September 30, 2025. Advance payments totaled $77,415 and $92,014 as of September 30, 2026 and December 31, 2025, respectively.

 

Manufacturing Service Agreement with TCNT for the AI Nose hardware products

 

On November 14, 2025, the Company entered into a manufacturing service agreement with TCNT to manufacture AI Nose hardware products. A deposit equal to 50% of the contract price was prepaid by the Company totaling $50,793 and $53,063 as of September 30, 2026 and December 31, 2025, respectively.

 

Lease agreement with director

 

The Company lease its office in Taiwan with a director of the Company for NT$50,000 (approximately US$1,570) per month. On June 1, 2026, the Company renew the office lease agreement for one year with the same lease amount till May 31, 2027.

 

12. Commitments and Contingencies

 

The Company operates in an industry characterized by extensive patent litigation. Competitors may claim that the Company’s products infringe upon their intellectual property. Resolution of patent litigation or other intellectual property claims is typically time consuming and costly and can result in significant damage awards and injunctions that could prevent the manufacture and sale of the affected products or require the Company to make significant royalty payments in order to continue selling the affected products. As of September 30, 2026, there were no such commitments or contingencies.

 

13. Subsequent Events

 

Manufacturing Service Agreement with TCNT for the AI Nose products

 

On October 20, 2026, the Company entered into additional manufacturing service agreement with TCNT to manufacture AI Nose products.

 

Sales Agreement with ASE

 

On November 12, 2026, the Company entered into a commercial sales agreement with ASE Technology Holding Co., Ltd. for the purchase of 5,000 units of AI NOSE equipment. The total purchase price is $9 million. Under the terms of the agreement, the customer shall pay 50% of the total purchase price within 60 days after agreement is signed, and the balance shall be paid upon completion and delivery of all the equipment.

 

The agreement is expected to contribute to future revenue and support the Company’s ongoing commercial operations.

 

19
 

 

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The unaudited condensed financial statements and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2025 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Form 10-K for the period ended December 31, 2025 (the “2025 Annual Report”). In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements are subject to risks and uncertainties, including those set forth under “Part I. Item 1A. Risk Factors” in our 2025 Annual Report, “Part II. Item 1A. Risk Factors” in this Quarterly Report, and elsewhere in this Quarterly Report, that could cause actual results to differ materially from historical results or anticipated results.

 

When used in this Quarterly Report, all references to “Ainos,” the “Company,” “we,” “our” and “us” refer to Ainos, Inc.

 

Overview

 

Ainos, Inc. (the “Company”) was incorporated in the State of Texas in 1984. The Company is a dual-platform company engaged in the development of artificial intelligence-enabled olfactory sensing technologies and related applications, which support our broader vision of Chemical Intelligence, as well as the development of immune therapeutics.

 

The Company’s principal operating focus is the commercialization of AI Nose, its proprietary scent digitization platform. AI Nose is designed to convert scent and volatile organic compound signals into structured, machine-readable data, which the Company refers to as “Smell ID,” using gas sensor arrays and proprietary artificial intelligence models. The Company is advancing AI Nose commercialization across selected industrial, semiconductor manufacturing, robotics, and healthcare-related applications.

 

In parallel, the Company continues to pursue the development and commercialization of VELDONA®, its low-dose oral interferon program, with an emphasis on selective advancement, capital-efficient execution, and strategic partnerships such as licensing arrangements and collaborations with third-party partners.

 

Employees

 

As of September 30, 2026, we had 41 full-time employees, of whom 20 were engaged in research and development. Most of our employees are based in Taiwan. None of our employees are represented by a labor union or are party to a collective bargaining agreement. We plan to continue to expand our workforce in research and development, sales and marketing, and general operations to support our business programs.

 

Our Execution Priorities for 2026

 

In 2026, the Company’s operating priorities are focused on advancing AI Nose commercialization activities while managing VELDONA® and other healthcare-related programs selectively and in a capital-efficient manner. Following initial industrial expansion activities in 2025, the Company’s current priorities include partner-led deployments, continued generation of scent-related data to support model refinement, and further advancement of commercial opportunities that may include hardware and service-based offerings. The Company may adjust the timing, scope, and prioritization of these activities based on available capital, regulatory developments, market conditions, partner execution, and other factors.

 

During the first three quarters of 2026, the Company continued to advance AI Nose deployment, validation, research, and commercialization activities across semiconductor manufacturing, industrial infrastructure, and healthcare-related environments. These activities included work relating to environmental monitoring, equipment and facility safety, emergency care environments, and research involving the analysis of exhaled breath patterns. These efforts remain at varying stages of deployment, validation, research, and commercialization.

 

AI Nose Operating Priorities

 

  ● Continue commercialization activities in selected applications.
  ● Continue semiconductor commercialization, deployment and validation efforts.
  ● Support commercialization through channel and integration partners.
  ● Continue development of proprietary artificial intelligence models and Smell ID datasets using deployment and pilot data to support the Company’s Chemical Intelligence strategy.
  ● Continue robotics-related pilot and deployment activities.
  ● Continue evaluating healthcare-adjacent applications.

 

VELDONA Operating Priorities

 

  ● Continue pursuing partnering and out-licensing opportunities.
  ● Support clinical development and commercialization activities through licensing and collaboration arrangements with third-party partners.

 

Factors Affecting Our Business

 

Our business activities continue to be influenced primarily by our emphasis on advancing AI Nose commercialization activities and managing healthcare-related programs selectively and in a capital-efficient manner. The timing, extent, and financial impact of these activities remain subject to a number of known trends and uncertainties, including the following:

 

Industrial and infrastructure-oriented applications.

 

We continue to prioritize AI Nose activities across industrial environments, including semiconductor manufacturing, robotics, smart manufacturing, and hospital infrastructure settings. Recent progress includes activities across front-end and backend semiconductor manufacturing environments through industry partners, robotics-related development initiatives and activities in hospital infrastructure environments. During the first three quarter of 2026, the Company continued AI Nose deployment and validation activities across certain facility monitoring, safety, ventilation, equipment, and chemical handling applications. These activities remain at varying stages of deployment, validation, and commercialization. The timing and extent of partner execution, customer adoption, and conversion of pilot and initial commercial activities into broader commercial arrangements may affect the timing of revenue and our near-term operating results.

 

Component supply and manufacturing.

 

The commercialization of AI Nose depends on the timely availability of components, electronic parts, and other materials from third-party suppliers. Changes in component availability, lead times, pricing, or broader supply chain conditions could increase costs, delay customer deployments, and adversely affect our commercialization activities, operating results, and financial condition.

 

20
 

 

Near-threshold technology development and system capabilities.

 

As part of our ongoing deployment and validation activities, we continue to develop AI Nose capabilities across different operating conditions and application environments. These efforts include the detection and interpretation of gas signal variations and the potential application of such capabilities in anomaly detection, environmental sensing, and operational monitoring. We are also developing AI Nose for near-threshold detection scenarios, meaning the detection of signal variations at or near traditional detection thresholds. If validated, such capabilities may support certain early-stage anomaly detection applications. We continue to develop these near-threshold detection capabilities with a focus on reliability, repeatability, and scalability across different environments, which remain subject to ongoing validation. Expanded deployments may provide additional conditions for evaluating system performance and environmental pattern recognition.

 

Data-driven platform development.

 

AI Nose deployments are expected to generate Smell ID data across different operating environments, and we continue to use this data to refine models, improve classification performance, and expand the range of detectable patterns. Continued deployment of AI Nose is also expected to result in further accumulation of scent-related data, which may support model improvement, broaden detectable patterns, and enhance system adaptability across different operating environments. During the first three quarters of 2026, the Company expanded data-generation activities across industrial and healthcare-related settings, including environmental signals, facility conditions, and exhaled breath patterns. While we expect these efforts to support ongoing performance improvements, the timing and extent to which they contribute to broader commercial adoption or commercial outcomes may vary, and their benefits may take time to be reflected in revenue or operating results.

 

Healthcare-adjacent opportunities.

 

We continue to develop AI Nose applications in senior care and other healthcare-adjacent settings, including environments where non-invasive and continuous sensing may support hygiene monitoring, environmental control, and hospital operations. During the first three quarters of 2026, the Company expanded research and validation activities in hospital infrastructure, emergency care, and exhaled breath analysis. These activities remain research- and validation-stage and are not intended to provide individual patient diagnosis. The timing and extent of these activities may be affected by regulatory requirements, partner engagement, operational validation, and resource allocation decisions.

 

VELDONA® program management.

 

We continue to focus VELDONA® on selected indications with unmet medical needs, including oral warts in HIV-seropositive patients, Sjögren’s syndrome, and feline chronic gingivostomatitis. The timing and direction of these programs may be affected by clinical outcomes, regulatory progress, partner interest, and available resources. We also continue to pursue strategic partnerships and out-licensing opportunities, the timing and outcome of which remain uncertain.

 

As of September 30, 2026, we had available cash and cash equivalents of $660,916. We anticipate business revenues and external financing options, if necessary, to fund our operations over the next twelve months. We have based this estimate on assumptions that may prove to be incorrect, and we could exhaust our available capital resources sooner than we expect. See “Liquidity and Capital Resources” for additional information. To finance our continuing operations, we will need to raise additional capital, which cannot be assured.

 

Recent Development

 

During the first three quarters of the year 2026, we advanced AI Nose-related activities within industrial applications, with a focus on semiconductor and robotics environments. These activities included

 

  ● Completing delivery of 1,400 AI Nose systems under an initial three-year $2.1 million commercial arrangement in back -end semiconductor manufacturing environments;
  ● Advancing from validation to initial commercial orders in selected front-end semiconductor manufacturing environments;

 

21
 

 

  ● Expanding AI Nose deployments and validation activities into industrial and healthcare infrastructure environments;
  ● Expanding research activities involving emergency care environments;
  ● Supporting use-case expansion through channel and integration partnerships;

 

These activities are intended to support continued development, capacity development and potential commercial expansion of AI Nose across industrial environments.

 

Separately, in the third quarter of 2026, we advanced the commercialization of VELDONA® by entering into an exclusive licensing agreement establishing a potential $10 million licensing framework, including an initial license for two indications - Sjögren’s disease and thrombocytopenia, with potential expansion into 15 additional indications, subject to future agreements and applicable conditions.

 

In the third quarter of 2026, we launched Atmosphere Engine, a modular platform based on electrochemical air-separation technology, designed to generate nitrogen and oxygen from ambient air at or near the point of use. The platform is initially intended for AI computing infrastructure and semiconductor manufacturing applications, expanding our capabilities from environmental sensing into active environmental management. We may also explore potential applications of its oxygen output in general healthcare, sports and other settings.

 

Results of Operations for Quarter Ended September 30, 2026 (“Q3 2026”) and September 30, 2025 (“Q3 2025”):

 

   The three months ended September 30,   Change 
   2026   2025   Amount   % 
Revenues  $642,889   $2,167   $640,722    29,567%
Cost of revenues   (106,623)   (477)   (106,146)   22,253%
Gross profit   536,266    1,690    534,576    31,632%
Operating expenses:                    
Research and development expenses   1,696,019    1,990,630    (294,611)   (15%)
Selling, general and administrative expenses   524,919    795,253    (270,334)   (34%)
Total operating expenses   2,220,938    2,785,883    (564,945)   (20%)
Loss from operations   (1,684,672)   (2,784,193)   1,099,521    (39%)
                     
Non-operating income (expenses), net                    
Interest expenses   (204,763)   (176,584)   (28,179)   16%
Other income (expenses), net   3,361    29,075    (25,714)   (88%)
Total non-operating expenses, net   (201,402)   (147,509)   (53,893)   37%
                     
Net loss before income taxes   (1,886,074)   (2,931,702)   1,045,628    (36%)
Provision for income taxes   -    -    -    - 
Net loss  $(1,886,074)  $(2,931,702)  $1,045,628    (36%)

 

Results of Operations reconciliation of GAAP to Non-GAAP Measures for Quarter Ended September 30, 2026 (“Q3 2026”) and September 30, 2025 (“Q3 2025”):

 

Non-GAAP Financial Measures

 

In addition to our GAAP results, we present Adjusted Net Loss, defined as net loss adjusted to exclude share-based compensation, depreciation and amortization, and (for the nine months ended September 30, 2025) common stock issued as a special stock bonus. Adjusted Net Loss does not exclude interest or income taxes and is not a measure of EBITDA. We also present certain expense and gross profit line items excluding share-based compensation and depreciation and amortization; the excluded amounts are disclosed with each line item below.

 

Management uses these measures to evaluate trends in cash operating costs. We believe they help investors assess the cash resources needed to fund our operations. However, share-based compensation is a recurring cost, and these measures do not reflect equity dilution, cash interest on our debt, or capital expenditures. Other companies may calculate similar measures differently. These measures should not be considered in isolation or as a substitute for net loss or other GAAP measures. The following table reconciles net loss to Adjusted Net Loss:

 

   The three months ended September 30,   Change 
   2026   2025   Amount   % 
GAAP net loss attributable to stockholders  $(1,886,074)  $(2,931,702)  $1,045,628    (36%)
Adjustments:                    
Stock-based compensation expense   21,305    348,356    (327,051)   (93%)
Depreciation and Amortization   1,192,417    1,206,641    (14,224)   (1%)
Non-GAAP net loss attributable to stockholders  $(672,352)  $(1,376,705)  $704,353    (51%)

 

Revenues, Cost and Gross Profit

 

The Company reported $642,889 and $2,167 in revenue in Q3 2026 and Q3 2025, respectively. The increase of revenue in Q3, 2026 was primarily driven by revenue generated from licensing the VELDONA Company’s intellectual property and the initial commercialization of AI Nose devices for semiconductor application. The Company generated $600,000 and nil from VELDONA licensing intellectual property and $42,750 and nil in revenues from AI Nose devices for semiconductor application and related programs in Q3 2026 and the same period in 2025, respectively.

 

The cost of revenue related to product sales in Q3 2026 was $106,623 compared to $477 in Q3 2025. The increase in cost of revenue was caused by the aforementioned cost of licensing VELDONA intellectual property and initial commercialization of AI Nose devices for semiconductor application during the reporting period.

 

The share-based compensation expense and the depreciation and amortization expense in Q3 2026 and Q3 2025 were $1,087 and nil respectively. When excluding these non-cash expenses, cost of revenue increased to $105,536 in Q3 2026 compared to $477 in Q3 2025.

 

Gross profit from product sales in Q3 2026 was $536,266 as compared to $1,690 gross profit from product sales in Q3 2025. The increase in gross profit was due to aforementioned VELDONA licensing agreement and initial commercialization of AI Nose devices for semiconductor application.

 

When excluding these non-cash expenses, Gross profit from product sales increased to $537,353 in Q3 2026 compared to $1,690 in Q3 2025.

 

Research and Development (R&D) Expenses

 

R&D expenses in Q3 2026 and Q3 2025 were $1,696,019 and $1,990,630, respectively. The decrease of $294,611 (15%) was due to reduced expenses in share-based compensation and expenses associated with co-research for technology partially.

 

The share-based compensation expense and the depreciation and amortization expense in Q3 2026 and Q3 2025 were $1,192,360 and $1,378,248, respectively. When excluding these non-cash expenses, R&D expenses decreased to $503,659 in Q3 2026 from $612,382 in Q3 2025.

 

Selling, General and Administrative (SG&A) Expenses

 

SG&A expenses were $524,919 and $795,253 in Q3 2026 and Q3 2025, respectively, reflecting a decrease of $270,334 (34%) due to a significant decrease in share-based compensation public relations and investor relations fees and professional fees.

 

22
 

 

The share-based compensation expense and the depreciation and amortization expense in Q3 2026 and Q3 2025 were $21,362 and $176,749 respectively. When excluding these non-cash expenses, SG&A expenses decreased to $503,557 in Q3 2026 compared to $618,504 in Q3 2025.

 

Operating Loss

 

The Company’s operating loss was $1,684,672 and $2,784,193 in Q3 2026 and Q3 2025, respectively, reflecting a $1,099,521 (39%) decrease in operating loss between the reporting periods. We continued to invest resources to execute our growth strategy and product roadmap to improve our profitability.

 

Interest Expense

 

In Q3 2026, interest expense was $204,763 compared to $176,584 in Q3 2025. The increase in interest expense was due to a new loan agreement in the first quarter of the year 2026.

 

Net Loss

 

Net loss was $1,886,074 in Q3 2026 compared to $2,931,702 in Q3 2025, resulting in an $1,045,628 (36%) decrease in net loss attributable to our shareholders of common stock.

 

Results of Operations for the first nine months of the year Ended September 30, 2026 (“the first nine month of year 2026”) and September 30, 2025 (“the first nine month of year 2025”):

 

The following table reconciles net loss to Adjusted Net Loss for the nine months ended September 30, 2026 and 2025. See “Non-GAAP Financial Measures” above for the definition of Adjusted Net Loss and a discussion of its usefulness and limitations.

 

   The nine months ended September 30,   Change 
   2026   2025   Amount   % 
Revenues  $643,202   $113,037   $530,165    469%
Cost of revenues   (107,439)   (19,647)   (87,792)   447%
Gross profit   535,763    93,390    442,373    474%
Operating expenses:                    
Research and development expenses   5,236,288    5,626,514    (390,226)   (7%)
Selling, general and administrative expenses   3,666,880    4,159,627    (492,747)   (12%)
Total operating expenses   8,903,168    9,786,141    (882,973)   (9%)
Loss from operations   (8,367,405)   (9,692,751)   1,325,346    (14%)
                     
Non-operating income (expenses), net                    
Interest expenses   (581,801)   (534,986)   (46,815)   9%
Other income (expenses), net   8,601    (74,977)   83,578    (111%)
Total non-operating expenses, net   (573,200)   (609,963)   36,763    (6%)
                     
Net loss before income taxes   (8,940,605)   (10,302,714)   1,362,109    (13%)
Provision for income taxes   -    -    -    - 
Net loss  $(8,940,605)  $(10,302,714)  $1,362,109    (13%)

 

23
 

 

Results of Operations reconciliation of GAAP to Non-GAAP Measures for the first nine months of the year Ended September 30, 2026 (“the first nine month of year 2026”) and September 30, 2025 (“the first nine month of 2025”):

 

   The nine months ended September 30,   Change 
   2026   2025   Amount   % 
GAAP net loss attributable to stockholders  $(8,940,605)  $(10,302,714)  $1,362,109    (13%)
Adjustments:                    
Stock-based compensation expense   2,033,926    1,728,055    305,870    18%
Stock issued for special stock bonus   -    862,230    (862,230)   (100%)
Depreciation and Amortization   3,553,809    3,578,083    (24,274)   (1%)
Non-GAAP net loss attributable to stockholders  $(3,352,870)  $(4,134,346)  $781,476    (19%)

 

Revenues, Cost and Gross Profit

 

The Company reported $643,202 and $113,037 in revenue in the first nine months of the year 2026 and the first nine months of the year 2025, respectively. The increase of revenue in the first nine months of the year 2026 was primarily driven by revenue generated from licensing the Company’s VELDONA intellectual property and the initial commercialization of AI Nose devices for semiconductor application. The Company generated $600,000 and nil from VELDONA licensing intellectual property and $42,750 and $106,329 in revenues from AI Nose devices for semiconductor application and related programs in the first nine months of the year 2026 and the first nine months of the year 2025, respectively.

 

The cost of revenue related to product sales in the first nine months of the year 2026 was $107,439 compared to $19,647 in the first nine months of the year 2025. The increase in cost of revenue was caused by the aforementioned cost of VELDONA licensing intellectual property and initial commercialization of AI Nose devices for semiconductor application during the reporting period.

 

The share-based compensation expense and the depreciation and amortization expense in the first nine months of the year 2026 and the first nine months of the year 2025 were $1,087 and nil respectively. When excluding these non-cash expenses, cost of revenue increased to $106,352 in the first nine months of the year 2026 compared to $19,647 in the first nine months of the year 2025.

 

Gross profit from product sales in the first nine months of the year 2026 was $535,763 as compared to $93,390 gross profit from product sales in the first nine months of the year 2025. The increase in gross profit was due to aforementioned VELDONA licensing agreement and initial commercialization of AI Nose devices for semiconductor application.

 

When excluding these non-cash expenses, Gross profit from product sales increased to $536,850 in the first nine months of the year 2026 compared to $93,390 in the first nine months of the year 2025.

 

Research and Development (R&D) Expenses

 

R&D expenses in the first nine months of the year 2026 and the first nine months of the year 2025 were $5,236,288 and $5,626,514, respectively. The decrease of $390,226 (7%) was due to reduced expenses in share-based compensation and expenses associated with co-research for technology partially. We expect that our R&D investments may continue to grow as we further develop our technologies.

 

The share-based compensation expense and depreciation and amortization expense in the first nine months of the year 2026 and the first nine months of the year 2025 were $3,534,383 and $3,780,461, respectively. When excluding these non-cash expenses, R&D expenses decreased to $1,701,905 in the nine months of the year 2026 from $1,846,053 in the nine months of the year 2025.

 

Selling, General and Administrative (SG&A) Expenses

 

SG&A expenses were $3,666,880 and $4,159,627 in the first nine months of the year 2026 and the first nine months of the year 2025, respectively, reflecting a decrease of $492,747 (12%) due to a significant decrease in share-based compensation and public relations and investor relations fees.

 

24
 

 

The share-based compensation expense and the depreciation and amortization expense in the first nine months of the year 2026 and the first nine months of the year 2025 were $2,052,265 and $2,387,907 respectively. When excluding these non-cash expenses, SG&A expenses decreased to $1,614,615 in the nine months of the year 2026 compared to $1,771,720 in the nine months of the year 2025.

 

Operating Loss

 

The Company’s operating loss was $8,367,405 and $9,692,751 in the first nine months of the year 2026 and the first nine months of the year 2025, respectively, reflecting a $1,325,346 (14%) decrease in operating loss between the reporting periods. We continued to invest resources to execute our growth strategy and product roadmap to improve our profitability.

 

Interest Expense

 

In the first nine months of the year 2026, interest expense was $581,801 compared to $534,986 in the first nine months of the year 2025. The increase in interest expense was due to the company processing a new loan agreement in the first quarter of the year 2026.

 

Net Loss

 

Net loss was $8,940,605 in the first nine months of the year 2026 compared to $10,302,714 in the first nine months of the year 2025, resulting in a $1,362,109 (13%) decrease in net loss attributable to our shareholders of common stock.

 

Liquidity and Capital Resources

 

As of September 30, 2026 and December 31, 2025, the Company had available cash of $660,916 and $417,353, respectively.

 

The following table summarizes our cash flow during the first nine months ended September 30, 2026 and 2025:

 

   For the nine months ended September 30, 
   2026   2025 
Net cash used in operating activities   (3,429,677)   (3,759,679)
Net cash provided (used) in investing activities   19,564    (13,112)
Net cash provided by financing activities   3,643,375    852,635 

 

Operating activities:

 

Net cash used in operating activities decreased by $330,002 during the first nine months of the year 2026 compared to the first nine months of the year 2025. Our net loss for the first nine months of the year 2026 decreased by $1,362,109 primarily due to the company lower operating expense. The operating cash outflow as a result of changes in operating assets and liabilities was mainly attributable to:

 

  ● Non-cash expenses including share-based compensation, depreciation and amortization, issuance cost of secured convertible note, and change in fair value of senior secured convertible note, issuance common stock for paying consulting fees decreased approximately by $505,600;
     
  ● Working capital injected into accounts receivable, inventories and other current assets decreased by approximately $671,000; and
     
  ● Working capital injected into accrued expenses, operating lease liabilities, contract liabilities and other current and long-term liabilities increased by approximately $144,400.

 

25
 

 

Investing activities

 

Net cash provided by (used in) for investing activities were $19,564 and ($13,112) during the first nine months of the year 2026 and the first nine months of the year 2025, respectively. The increase was due to a reduction in refundable deposits and other noncurrent assets and decrease in purchases of property and equipment and increase in proceeds from disposal of property and equipment.

 

Financing activities

 

Cash provided by financing activities were $3,643,375 and $852,635 during the first nine months of the year 2026 and the first nine months of the year 2025, respectively. The $2,790,740 increase was primarily reflected by the following:

 

  ● Proceeds from loan payable financing increased by $2,812,940; and
  ● Proceeds from at-the-market offering, net of issuance costs decreased by $1,022,460; and
  ● Repayments of convertible note decreased by $1,000,000; and
  ● Fractional shares paid out in cash for the reverse stock split decrease by $260

 

In the near-term, we expect to invest in our product development activities to advance our product pipeline. We may also increase our sales and marketing efforts.

 

Subsequent to September 30, 2026, the Company received $600,000 in outstanding accounts receivable related to its VELDONA® intellectual property licensing agreement and $350,000 associated with its AI Nose commercialization activities in semiconductor manufacturing. These collections, totaling $950,000, strengthened the Company’s liquidity position and increased its cash resources compared to September 30, 2026. Management believes these additional resources will support the Company’s ongoing operating activities, working capital requirements, and planned business initiatives.

 

The Company anticipates that cash reserves, business revenues, and potential debt financing through convertible and non-convertible notes will fund the Company’s operations over the next twelve months. There can be no assurance that we will be successful in our efforts to make the Company profitable. If those efforts are not successful, the Company may raise additional capital through the issuance of equity securities, debt financings or other sources to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan.

 

Critical Accounting Policies and Significant Management Estimates

 

Our management’s discussion and analysis of our financial condition and results of operations are based on our unaudited condensed financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses.

 

We evaluate our estimates and judgments, including those related to inventory valuation, useful lives of property and equipment, valuation of stock option, warrants and convertible note, and impairment testing of intangible assets, on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

26
 

 

There have been no material changes to our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in “Management’s Discussion and Analysis - Critical Accounting Policies and Significant Management Estimates” of our 2025 Annual Report, except for those accounting subjects discussed in the Notes, if any, to the unaudited condensed financial statements included in this Quarterly Report on Form 10-Q.

 

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

 

We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 3.

 

ITEM 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2026.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal controls over financial reporting during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II - OTHER INFORMATION

 

ITEM 1. Legal Proceedings

 

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. As of the date of this report, we were not aware of any material legal proceedings involving the Company.

 

ITEM 1A. Risk Factors

 

This Quarterly Report contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed in this Quarterly Report. Factors that could cause or contribute to these differences include, but are not limited to, those discussed below and elsewhere in this Quarterly Report.

 

You should carefully consider the risk factors disclosed in our 2025 Annual Report, together with all other information in this Quarterly Report, including our unaudited condensed financial statements and notes thereto, and in our other filings with the Securities and Exchange Commission. If any such risks, including the risk set out below, or other risks not presently known to us or that we currently believe to not be significant, develop into actual events, then our business, financial condition, results of operations or prospects could be materially adversely affected. If that happens, the market price of our common stock could decline, and stockholders may lose all or part of their investment.

 

Information on risk factors can be found in Part I, Item 1A (Risk Factors) of our 2025 Annual Report. Other than the following risk factor, there have been no material changes from the risk factors previously disclosed in our 2025 Annual Report, other than the risk factor set forth below.

 

27
 

 

Fluctuating foreign currency and exchange rates may negatively impact our business, results of operations, and financial position.

 

Due to our foreign operations, a portion of our business is denominated in foreign currencies. As a result, fluctuations in foreign currency and exchange rates may have an impact on our business, results of operations and financial position. Foreign currency exchange rates have fluctuated and may continue to fluctuate. Significant foreign currency exchange rate fluctuations may negatively impact our international revenue, which in turn would affect our consolidated revenue. Currencies may be affected by internal factors, general economic conditions and external developments in other countries, all of which can have an adverse impact on a country’s currency. We cannot predict whether we will incur foreign exchange losses in the future. Further, significant foreign exchange fluctuations resulting in a decline in the respective local currency may decrease the value of our foreign assets, as well as decrease our revenues and earnings from our foreign subsidiaries, which would reduce our profitability and adversely affect our financial position.

 

Policy changes affecting international trade could adversely impact the demand for our products and our competitive position.

 

Changes in government policies on foreign trade and investment can affect the demand for our products and services, impact the competitive position of our products and services or prevent us from being able to sell products and services in certain countries. The implementation of more restrictive trade policies, such as more detailed inspections, higher tariffs, import or export licensing requirements, economic sanctions, anti-boycott laws, exchange controls or new barriers to entry could have a material adverse effect on our business, financial condition, results of operations and cash flows. In addition, the Trump Administration has announced tariffs on certain imports from Canada, Mexico and the EU, among others, that could affect the demand for our products. Such tariffs and any retaliatory tariffs (including those announced by China, Canada and Mexico) may put upwards pressure on prices in other jurisdictions from which we purchase product components, which could reduce our ability to offer competitive pricing to potential customers. We cannot predict what changes to trade policy will be made by the Trump Administration, the U.S. Congress or other governments, including whether existing tariff policies will be maintained or modified or whether the entry into new bilateral or multilateral trade agreements will occur, nor can we predict the effects that any such changes would have on our business or the global economy. Changes in U.S. trade policy, or threat of such changes, have resulted and could again result in reactions from U.S. trading partners, including adopting responsive trade policies making it more difficult or costly for us to export our products or import products or product components from countries where we currently purchase products or product components or sell products or services. Such changes, or threatened changes, to trade policy or in laws and policies governing foreign trade, and any resulting negative sentiments towards the United States as a result of such changes, could materially and adversely affect our business, financial condition, results of operations and liquidity.

 

We may be unable to maintain compliance with the continued listing requirements of The Nasdaq Capital Market, and our common stock could be delisted.

 

Our common stock is listed on The Nasdaq Capital Market, which imposes continued listing requirements, including a minimum bid price of $1.00 per share, minimum stockholders’ equity or market value requirements, and corporate governance standards. As of September 30, 2026, we had a stockholders’ equity of $1,721,037, which is below the $2,500,000 minimum stockholders’ equity requirement of Nasdaq Listing Rule 5550(b)(1). If Nasdaq determines that we do not satisfy that requirement or one of the alternative continued listing standards under Nasdaq Listing Rule 5550(b), we could receive a deficiency notice or a delisting determination. There can be no assurance that we will maintain compliance with the applicable continued listing requirements. If our common stock were delisted, the liquidity and market price of our common stock would likely be materially adversely affected, our ability to raise capital would be impaired, and our common stock could become subject to the “penny stock” rules, which could further limit trading in our common stock.

 

28
 

 

ITEM 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities

 

Recent Sales of Unregistered Equity Securities

 

As of September 30, 2026, the Company has issued 19,531 unregistered securities to pursue a marketing service agreement.

 

Unless otherwise stated above, the issuances of these securities were made in reliance upon exemptions provided by Section 4(a)(2) of the Securities Act, Regulation D promulgated thereunder, or Securities Act Rule 701 for the offer and sale of securities not involving a public offering.

 

Issuer Purchase of Equity Securities

 

Not applicable.

 

Use of Proceeds of Registered Securities

 

Not applicable.

 

ITEM 3. Defaults Upon Senior Securities

 

None

 

ITEM 4. Mine Safety Disclosures

 

Not applicable.

 

ITEM 5. Other Information

 

We are reporting the following information in lieu of reporting on a Current Report on Form 8-K under Item1.01 Entry into a Material Definitive Agreement, and Item 3.02, Unregistered Sales of Equity Securities.

 

29
 

 

Insider trading arrangements and policies.

 

During the quarter ended September 30, 2026, no director or officer of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

ITEM 6. Exhibits

 

EXHIBIT INDEX

 

            INCORPORATED BY REFERENCE
EXHIBIT NUMBER   DESCRIPTION  

FILED WITH THIS

FORM 10-Q

 

FILING DATE

WITH SEC

  FORM   EXH #   HYPERLINK
TO FILINGS
3.1   Second Amended and Restated Bylaws of Ainos, Inc.       10/16/2026   8-K   3.1   Second Amended and Restated Bylaws of Ainos, Inc.
10.1   Global Exclusive License Agreement, dated September 24, 2026, by and between Ainos, Inc. and BioPhoenix Co., Ltd       09/28/2026   8-K   10.1   Global Exclusive License Agreement
31.1   Certification of Chief Executive Officer Pursuant to Rule 13a- 14(a) / 15d – 14(a)   x                
31.2   Certification of Chief Financial Officer Pursuant to Rule 13a- 14(a) / 15d – 14(a)   x                
32.1   Certification Of Principal Executive Officer Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 Of The Sarbanes-Oxley Act Of 2002   x                
32.2   Certification Of Principal Financial Officer Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 Of The Sarbanes-Oxley Act Of 2002   x                
99.1   Corporate Governance Policies of the Board of Directors, as amended       10/16/2026   8-K   99.1   Corporate Governance Policies of the Board of Directors, as amended
100   Inline XBRL – Related Documents   x                
101.INS   Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the XBRL document.   x                
101.SCH   Inline XBRL Taxonomy Extension Schema Document   x                
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase   x                
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase   x                
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase   x                
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase   x                
104.1   Cover Page Interactive Data File   x                

 

The exhibits listed in the Exhibit Index are filed or incorporated by reference as part of this filing.

 

30
 

 

SIGNATURES

 

Pursuant to the requirements of Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  AINOS, INC.
     
Date: November 16, 2026 By: /s/ Chun-Hsien Tsai
    Chun-Hsien Tsai, Chairman of the Board, President, and Chief Executive Officer
     
Date: November 16, 2026 By: /s/ Hsin-Liang Lee
    Hsin-Liang Lee, Chief Financial Officer

 

31

Keep reading